Finance

Lists
Why is MGX down 10,07%?
Dive Deeper
MGX:NASDAQ
Metagenomi Therapeutics Inc
0,92 $
-10,07%
(-0,10) 1D
0,91 $
-0,56% (-0,0051)
After hours
Closed: 13 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
1,02 $
High
1,03 $
Low
0,91 $
Mkt. cap
34,65 մլն
Avg. vol.
161,65 հզր
Volume
263,66 հզր
52-wk high
3,95 $
52-wk low
0,91 $
EPS
-2,49 $
Shares outstanding
37,78 մլն
No. of employees
113
Open
1,02 $
High
1,03 $
Low
0,91 $
Mkt. cap
34,65 մլն
Avg. vol.
161,65 հզր
Volume
263,66 հզր
52-wk high
3,95 $
52-wk low
0,91 $
EPS
-2,49 $
Shares outstanding
37,78 մլն
No. of employees
113
News stories
From web sources and news partners
About Metagenomi Therapeutics Inc
CEO-
Employees113
Founded2016
HeadquartersԷմերիվիլ, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitemetagenomi.co
Analyst ratings
Based on 4 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current 0,92 $
7,00 $ (+663,11%)
Average
6,00 $ (+554,09%)
Lowest
5,00 $ (+445,08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/11/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
7,00 $
+663,1%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
5,00 $
+445,1%
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
5,00 $
+445,1%
07/07/2026
Last report
10 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,73 $ / -0,52 $
-40,38%miss
Revenue / Est. (USD)
-257,00 հզր / 2,93 մլն
-108,76%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
8,66 մլն
3,91 մլն
1,25 մլն
-257,00 հզր
Cost of goods sold
25,28 մլն
21,50 մլն
19,30 մլն
22,51 մլն
Cost of revenue
25,28 մլն
21,50 մլն
19,30 մլն
22,51 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,22 մլն
6,78 մլն
6,54 մլն
6,00 մլն
Operating expense
6,22 մլն
6,78 մլն
6,54 մլն
6,00 մլն
Total operating expenses
31,50 մլն
28,28 մլն
25,84 մլն
28,52 մլն
Operating income
-22,84 մլն
-24,37 մլն
-24,59 մլն
-28,77 մլն
Other non operating income
-2,00 հզր
-11,00 հզր
-1,00 հզր
35,00 հզր
EBT including unusual items
-20,63 մլն
-22,49 մլն
-23,05 մլն
-27,48 մլն
EBT excluding unusual items
-20,63 մլն
-22,49 մլն
-23,05 մլն
-27,48 մլն
Income tax expense
-234,00 հզր
34,00 հզր
10,00 հզր
-
Effective tax rate
1,13%
-0,15%
-0,04%
-
Other operating expenses
-
-
-
-
Net income
-20,39 մլն
-22,53 մլն
-23,06 մլն
-27,48 մլն
Net profit margin
-235,51%
-576,02%
-1 847,68%
10 693,39%
Earnings per share
-0,55
-0,60
-0,61
-0,73
Interest and investment income
2,21 մլն
1,88 մլն
1,54 մլն
1,26 մլն
Interest expense
-
-
-
-
Net interest expenses
2,21 մլն
1,88 մլն
1,54 մլն
1,26 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,52 մլն
-23,07 մլն
-23,31 մլն
-27,51 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google Apps